دورية أكاديمية
أعرض في EDS

A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.

التفاصيل البيبلوغرافية
العنوان: A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
المؤلفون: Duquette P; Notre-Dame Hospital, Université de Montréal, Montreal, Quebec, Canada., Yeung M; University of Calgary Multiple Sclerosis Clinic, Calgary, Alberta, Canada., Mouallif S; Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada., Nakhaipour HR; Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada., Haddad P; Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada., Schecter R; Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada.
المصدر: PloS one [PLoS One] 2019 Jan 14; Vol. 14 (1), pp. e0210417. Date of Electronic Publication: 2019 Jan 14 (Print Publication: 2019).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Fingolimod Hydrochloride/*therapeutic use , Immunosuppressive Agents/*therapeutic use , Multiple Sclerosis, Relapsing-Remitting/*drug therapy, Canada ; Crotonates/therapeutic use ; Dimethyl Fumarate/therapeutic use ; Humans ; Hydroxybutyrates ; Insurance Claim Review ; Natalizumab/therapeutic use ; Nitriles ; Patient Compliance ; Retrospective Studies ; Toluidines/therapeutic use
مستخلص: Background: Compliance to disease modifying therapy (DMT) is associated with a reduced risk of relapse, lower healthcare resource utilization, and improved health-related quality of life in patients with multiple sclerosis (MS). Our objective was to assess the compliance and discontinuation rates of fingolimod relative to other oral, injectable, and infusible DMTs available on the market at the time of the study in Canada in patients with relapsing-remitting MS (RRMS).
Methods and Findings: We conducted a retrospective claims analysis. Patients with RRMS with ≥ 1 prescription for each DMT were included. Compliance (medication possession ratio of ≥ 80%) and discontinuation (gap > 30 days from the end of the index prescription) were calculated at the 6-, 12- and 24-month time points. Compliance with fingolimod at the 6-, 12- and 24-month time points was 75%, 75% and 70%, respectively; compared with DMF [70% (P < 0.001), 68% (P < 0.001), and 56% (P < 0.001), respectively], and BRACE [53% (P < 0.001), 47% (P < 0.001), and 35% (P < 0.001), respectively]. Compliance with fingolimod was comparable to teriflunomide at each time point, but was higher compared to natalizumab [70% versus 57% (P < 0.001)] at the 24-month time point. At the 6-, 12- and 24-month time points, patients on fingolimod had the lowest discontinuation rate (26%, 24%, and 29%, respectively) compared to BRACE [49% (P < 0.001), 44% (P < 0.001), and 57% (P < 0.001)], respectively], and natalizumab [33% (P < 0.001), 29% (P < 0.001), and 45% (P < 0.001), respectively], and was similar to teriflunomide (26%, 25%, and 31%, respectively).
Conclusions: The compliance rate in fingolimod treated patients at the 24 month time point was higher than that observed in natalizumab treated patients. The discontinuation rate was lower with fingolimod compared to other DMTs at all time points but was similar to teriflunomide.
Competing Interests: This research was funded by Novartis Pharmaceuticals Canada Inc. Pierre Duquette has received honoraria for advisory board participation and for CMEs from Novartis, Biogen-Idec, Genzyme, EMD Serono, and Teva Neuroscience. He has participated in the investigator-initiated trials funded by Novartis, Biogen-Idec, Genzyme, and EMD Serono and has received funding from peer-reviewed agencies, such as the Canadian Institutes for Health Research (CIHR) and the MS Society of Canada. He did not receive any compensation for his involvement in this work. Michael Yeung has received consultation fees from EMD Serono, Genzyme, Novartis, and the Canadian Agency for Drugs and Technologies in Health (CADTH)/Health Canada and research support from Biogen-Idec, Genzyme, Hoffmann-La Roche, Novartis, and Teva Canada Innovation. He did not receive any compensation for his involvement in this work. Soukaina Mouallif, Hamid Reza Nakhaipour, Paola Haddad, and Robyn Schecter are employees of Novartis Pharmaceuticals Canada Inc. The specific roles of these authors are articulated in the ‘author contributions’ section. With reference to PLOS ONE policies on sharing data and materials, we confirm that this does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.
References: Eur J Neurol. 2011 Jan;18(1):69-77. (PMID: 20561039)
Can J Neurol Sci. 2018 Sep;45(5):489-503. (PMID: 29893652)
J Med Econ. 2014 Oct;17(10):696-707. (PMID: 25019581)
BMC Neurol. 2013 Oct 04;13:138. (PMID: 24093542)
J Manag Care Spec Pharm. 2017 Aug;23(8):844-852. (PMID: 28737986)
Patient Prefer Adherence. 2011 Feb 27;5:101-8. (PMID: 21448467)
BMJ. 2016 Aug 22;354:i3518. (PMID: 27549763)
J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S24-40. (PMID: 23383731)
Lancet Neurol. 2011 Jun;10(6):520-9. (PMID: 21571593)
Int J MS Care. 2013 Spring;15(1):36-45. (PMID: 24453761)
Adv Ther. 2011 Jan;28(1):51-61. (PMID: 21153000)
J Clin Epidemiol. 1997 Jan;50(1):105-16. (PMID: 9048695)
J Neurol. 2009 Apr;256(4):568-76. (PMID: 19444532)
Value Health. 2008 Jan-Feb;11(1):44-7. (PMID: 18237359)
J Med Econ. 2015;18(9):711-20. (PMID: 25903661)
CNS Drugs. 2009;23(6):453-62. (PMID: 19480465)
Clin Drug Investig. 2010;30(2):89-100. (PMID: 20067327)
J Med Econ. 2011;14(6):739-47. (PMID: 21913796)
N Engl J Med. 2010 Feb 4;362(5):387-401. (PMID: 20089952)
المشرفين على المادة: 0 (Crotonates)
0 (Hydroxybutyrates)
0 (Immunosuppressive Agents)
0 (Natalizumab)
0 (Nitriles)
0 (Toluidines)
1C058IKG3B (teriflunomide)
FO2303MNI2 (Dimethyl Fumarate)
G926EC510T (Fingolimod Hydrochloride)
تواريخ الأحداث: Date Created: 20190115 Date Completed: 20191021 Latest Revision: 20211204
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6331106
DOI: 10.1371/journal.pone.0210417
PMID: 30640935
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0210417